Heart Failure Drugs Market 2027 By Drugs | The Insight Partners

Heart Failure Drugs Market to 2027 - Global Analysis and Forecasts by Drugs (Beta Blockers, ARBs, ACE inhibitors)

Report Code: TIPRE00004602 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Heart Failure is a major chronic disease where the heart muscle stops pumping blood or pumps abnormally. Heart failure drugs are generic in nature and is very common in the market owing to increasing cardiac arrests and heart failures.

MARKET DYNAMICS
The Heart Failure Drugs market is anticipated to grow in the forecast period owing to driving factors such as increasing geriatric population, growing prevalence of chronic diseases, growing prevalence of Diabetes, hypertension, high cholesterol, lack of awareness, and lack of treatment facilities.

MARKET SCOPE
The "Global Heart Failure Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of Heart Failure Drugs market with detailed market segmentation by Drugs and geography. The global Heart Failure Drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Heart Failure Drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Heart Failure Drugs market is segmented on the basis of Drugs. Based on Drugs the market is segmented into Beta Blockers, ARBs, ACE inhibitors.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Heart Failure Drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Heart Failure Drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Heart Failure Drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Heart Failure Drugs market in these regions.

MARKET PLAYERS
The reports cover key developments in the Heart Failure Drugs Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Heart Failure Drugs Market are anticipated to lucrative growth opportunities in the future with the rising demand for Heart Failure Drugs in the global market. Below mentioned is the list of few companies engaged in the Heart Failure Drugs market.

The report also includes the profiles of key Heart Failure Drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Amgen
  • AstraZeneca
  • Bayer
  • Novartis
  • Gilead
  • GlaxoSmithKline
  • Pfizer
  • Teva Pharmaceutical industries
  • Cardurion Pharmaceuticals
  • Cardior Pharmaceuticals GmbH
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Heart Failure Drugs Market - By Drugs
1.3.2 Heart Failure Drugs Market - By Region
1.3.2.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. HEART FAILURE DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. HEART FAILURE DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. HEART FAILURE DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. HEART FAILURE DRUGS - GLOBAL MARKET OVERVIEW
6.2. HEART FAILURE DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. HEART FAILURE DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUGS
7.1. OVERVIEW
7.2. DRUGS MARKET FORECASTS AND ANALYSIS
7.3. BETA BLOCKERS
7.3.1. Overview
7.3.2. Beta Blockers Market Forecast and Analysis
7.4. ARBS
7.4.1. Overview
7.4.2. ARBs Market Forecast and Analysis
7.5. ACE INHIBITORS
7.5.1. Overview
7.5.2. ACE inhibitors Market Forecast and Analysis
8. HEART FAILURE DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1 North America Heart Failure Drugs Market Overview
8.1.2 North America Heart Failure Drugs Market Forecasts and Analysis
8.1.3 North America Heart Failure Drugs Market Forecasts and Analysis - By Drugs
8.1.4 North America Heart Failure Drugs Market Forecasts and Analysis - By Countries
8.1.4.1 United States Heart Failure Drugs Market
8.1.4.1.1 United States Heart Failure Drugs Market by Drugs
8.1.4.2 Canada Heart Failure Drugs Market
8.1.4.2.1 Canada Heart Failure Drugs Market by Drugs
8.1.4.3 Mexico Heart Failure Drugs Market
8.1.4.3.1 Mexico Heart Failure Drugs Market by Drugs
8.1.4.4 US Heart Failure Drugs Market
8.1.4.4.1 US Heart Failure Drugs Market by Drugs
8.2. EUROPE
8.2.1 Europe Heart Failure Drugs Market Overview
8.2.2 Europe Heart Failure Drugs Market Forecasts and Analysis
8.2.3 Europe Heart Failure Drugs Market Forecasts and Analysis - By Drugs
8.2.4 Europe Heart Failure Drugs Market Forecasts and Analysis - By Countries
8.2.4.1 Germany Heart Failure Drugs Market
8.2.4.1.1 Germany Heart Failure Drugs Market by Drugs
8.2.4.2 France Heart Failure Drugs Market
8.2.4.2.1 France Heart Failure Drugs Market by Drugs
8.2.4.3 Italy Heart Failure Drugs Market
8.2.4.3.1 Italy Heart Failure Drugs Market by Drugs
8.2.4.4 Spain Heart Failure Drugs Market
8.2.4.4.1 Spain Heart Failure Drugs Market by Drugs
8.2.4.5 United Kingdom Heart Failure Drugs Market
8.2.4.5.1 United Kingdom Heart Failure Drugs Market by Drugs
8.3. ASIA-PACIFIC
8.3.1 Asia-Pacific Heart Failure Drugs Market Overview
8.3.2 Asia-Pacific Heart Failure Drugs Market Forecasts and Analysis
8.3.3 Asia-Pacific Heart Failure Drugs Market Forecasts and Analysis - By Drugs
8.3.4 Asia-Pacific Heart Failure Drugs Market Forecasts and Analysis - By Countries
8.3.4.1 Australia Heart Failure Drugs Market
8.3.4.1.1 Australia Heart Failure Drugs Market by Drugs
8.3.4.2 China Heart Failure Drugs Market
8.3.4.2.1 China Heart Failure Drugs Market by Drugs
8.3.4.3 India Heart Failure Drugs Market
8.3.4.3.1 India Heart Failure Drugs Market by Drugs
8.3.4.4 Japan Heart Failure Drugs Market
8.3.4.4.1 Japan Heart Failure Drugs Market by Drugs
8.4. MIDDLE EAST AND AFRICA
8.4.1 Middle East and Africa Heart Failure Drugs Market Overview
8.4.2 Middle East and Africa Heart Failure Drugs Market Forecasts and Analysis
8.4.3 Middle East and Africa Heart Failure Drugs Market Forecasts and Analysis - By Drugs
8.4.4 Middle East and Africa Heart Failure Drugs Market Forecasts and Analysis - By Countries
8.4.4.1 South Africa Heart Failure Drugs Market
8.4.4.1.1 South Africa Heart Failure Drugs Market by Drugs
8.4.4.2 Saudi Arabia Heart Failure Drugs Market
8.4.4.2.1 Saudi Arabia Heart Failure Drugs Market by Drugs
8.4.4.3 U.A.E Heart Failure Drugs Market
8.4.4.3.1 U.A.E Heart Failure Drugs Market by Drugs
8.5. SOUTH AND CENTRAL AMERICA
8.5.1 South and Central America Heart Failure Drugs Market Overview
8.5.2 South and Central America Heart Failure Drugs Market Forecasts and Analysis
8.5.3 South and Central America Heart Failure Drugs Market Forecasts and Analysis - By Drugs
8.5.4 South and Central America Heart Failure Drugs Market Forecasts and Analysis - By Countries
8.5.4.1 Brazil Heart Failure Drugs Market
8.5.4.1.1 Brazil Heart Failure Drugs Market by Drugs
8.5.4.2 Argentina Heart Failure Drugs Market
8.5.4.2.1 Argentina Heart Failure Drugs Market by Drugs
9. INDUSTRY LANDSCAPE
9.1. MERGERS AND ACQUISITIONS
9.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
9.3. NEW PRODUCT LAUNCHES
9.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
10. HEART FAILURE DRUGS MARKET, KEY COMPANY PROFILES
10.1. AMGEN
10.1.1. Key Facts
10.1.2. Business Description
10.1.3. Products and Services
10.1.4. Financial Overview
10.1.5. SWOT Analysis
10.1.6. Key Developments
10.2. ASTRAZENECA
10.2.1. Key Facts
10.2.2. Business Description
10.2.3. Products and Services
10.2.4. Financial Overview
10.2.5. SWOT Analysis
10.2.6. Key Developments
10.3. BAYER
10.3.1. Key Facts
10.3.2. Business Description
10.3.3. Products and Services
10.3.4. Financial Overview
10.3.5. SWOT Analysis
10.3.6. Key Developments
10.4. NOVARTIS
10.4.1. Key Facts
10.4.2. Business Description
10.4.3. Products and Services
10.4.4. Financial Overview
10.4.5. SWOT Analysis
10.4.6. Key Developments
10.5. GILEAD
10.5.1. Key Facts
10.5.2. Business Description
10.5.3. Products and Services
10.5.4. Financial Overview
10.5.5. SWOT Analysis
10.5.6. Key Developments
10.6. GLAXOSMITHKLINE
10.6.1. Key Facts
10.6.2. Business Description
10.6.3. Products and Services
10.6.4. Financial Overview
10.6.5. SWOT Analysis
10.6.6. Key Developments
10.7. PFIZER
10.7.1. Key Facts
10.7.2. Business Description
10.7.3. Products and Services
10.7.4. Financial Overview
10.7.5. SWOT Analysis
10.7.6. Key Developments
10.8. TEVA PHARMACEUTICAL INDUSTRIES
10.8.1. Key Facts
10.8.2. Business Description
10.8.3. Products and Services
10.8.4. Financial Overview
10.8.5. SWOT Analysis
10.8.6. Key Developments
10.9. CARDURION PHARMACEUTICALS
10.9.1. Key Facts
10.9.2. Business Description
10.9.3. Products and Services
10.9.4. Financial Overview
10.9.5. SWOT Analysis
10.9.6. Key Developments
10.10. CARDIOR PHARMACEUTICALS GMBH
10.10.1. Key Facts
10.10.2. Business Description
10.10.3. Products and Services
10.10.4. Financial Overview
10.10.5. SWOT Analysis
10.10.6. Key Developments
11. APPENDIX
11.1. ABOUT THE INSIGHT PARTNERS
11.2. GLOSSARY OF TERMS
The List of Companies

- Amgen
- AstraZeneca
- Bayer
- Novartis
- Gilead
- GlaxoSmithKline
- Pfizer
- Teva Pharmaceutical industries
- Cardurion Pharmaceuticals
- Cardior Pharmaceuticals GmbH